Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Precigen ( (PGEN) ).
Precigen, Inc. has reclaimed all rights to its technology following the termination of its Amended and Restated License Agreement with Alaunos Therapeutics, Inc., effectively revoking any access Alaunos once had. This marks a significant shift in control over the licensed technology since the original agreement in 2018.
Learn more about PGEN stock on TipRanks’ Stock Analysis page.
